Pfizer moves ahead with once-a-day weight loss pills

(Reuters) – Pfizer said on Thursday it would advance a revamped once-a-day version of its experimental obesity pill, danuglipron, into clinical trials in the second half of this year, sending its shares 5% higher in premarket trading.

The drugmaker said last year it was focusing on danuglipron’s development after scrapping a separate once-daily pill over liver safety concerns.

Pfizer tested both a once-daily modified-release dosage and also a twice-daily form of danugliprone.

It said early study results supported once-daily dosing, with a safety profile consistent with previous twice-daily dosing studies of danugliprone, including no liver enzyme elevations observed in more than 1,400 healthy adult volunteers.

The Pfizer drug is part of the second generation of weight loss pills, under development by companies such as Eli Lilly and Novo Nordisk, which will offer patients more convenient dosing instead of injections.

(Reporting by Manas Mishra in Bengaluru; Editing by Shinjini Ganguli)

Back To Top